StocksFundsScreenerSectorsWatchlists
GH

GH - Guardant Health Inc Stock Price, Fair Value and News

18.29USD-0.39 (-2.09%)Market Closed

Market Summary

GH
USD18.29-0.39
Market Closed
-2.09%

GH Alerts

  • 1 major insider buys recently.

GH Stock Price

View Fullscreen

GH RSI Chart

GH Valuation

Market Cap

2.2B

Price/Earnings (Trailing)

-4.64

Price/Sales (Trailing)

3.95

EV/EBITDA

-5.15

Price/Free Cashflow

-6.44

GH Price/Sales (Trailing)

GH Profitability

EBT Margin

-84.90%

Return on Equity

-302.14%

Return on Assets

-26.84%

Free Cashflow Yield

-15.52%

GH Fundamentals

GH Revenue

Revenue (TTM)

563.9M

Rev. Growth (Yr)

22.19%

Rev. Growth (Qtr)

8.41%

GH Earnings

Earnings (TTM)

-479.4M

Earnings Growth (Yr)

-33.67%

Earnings Growth (Qtr)

-117.23%

Breaking Down GH Revenue

Last 7 days

3.7%

Last 30 days

-3.7%

Last 90 days

-24.4%

Trailing 12 Months

-26.3%

How does GH drawdown profile look like?

GH Financial Health

Current Ratio

6.54

Debt/Equity

7.18

Debt/Cashflow

-0.29

GH Investor Care

Shares Dilution (1Y)

18.55%

Diluted EPS (TTM)

-4.3

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023482.2M510.2M535.8M563.9M
2022391.1M408.1M430.8M449.5M
2021297.9M323.7M343.9M373.7M
2020245.2M257.6M271.3M286.7M
2019110.6M145.2M184.4M214.4M
201860.0M70.2M80.4M90.6M
20170037.5M49.8M
201600025.2M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Guardant Health Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 04, 2024
joyce meghan v.
acquired
-
-
67.00
-
Apr 01, 2024
freeman chris
sold (taxes)
-10,752
20.25
-531
chief commercial officer
Apr 01, 2024
chudova darya
acquired
-
-
1,340
chief technology officer
Apr 01, 2024
kalia kumud
acquired
-
-
1,607
chief information officer
Apr 01, 2024
eagle craig
acquired
-
-
1,714
chief medical officer
Apr 01, 2024
freeman chris
acquired
-
-
1,929
chief commercial officer
Apr 01, 2024
chudova darya
sold (taxes)
-10,671
20.25
-527
chief technology officer
Apr 01, 2024
kalia kumud
sold (taxes)
-11,623
20.25
-574
chief information officer
Apr 01, 2024
saia john g.
acquired
-
-
974
chief legal officer
Apr 01, 2024
eagle craig
sold (taxes)
-12,575
20.25
-621
chief medical officer

1–10 of 50

Which funds bought or sold GH recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 10, 2024
Green Alpha Advisors, LLC
sold off
-100
-208,610
-
-%
Apr 09, 2024
MASSMUTUAL TRUST CO FSB/ADV
sold off
-100
-1,542
-
-%
Apr 09, 2024
ADIRONDACK TRUST CO
unchanged
-
186
2,371
-%
Apr 05, 2024
LOS ANGELES CAPITAL MANAGEMENT LLC
sold off
-100
-400,151
-
-%
Apr 05, 2024
NBC SECURITIES, INC.
unchanged
-
-1,000
2,000
-%
Apr 05, 2024
GAMMA Investing LLC
added
70.00
132
351
-%
Apr 05, 2024
CWM, LLC
reduced
-22.83
-6,000
9,000
-%
Apr 03, 2024
Versant Capital Management, Inc
sold off
-100
-568
-
-%
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
reduced
-64.34
-66,004
31,838
-%
Mar 21, 2024
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND
unchanged
-
-147,630
1,541,850
-%

1–10 of 36

Are Funds Buying or Selling GH?

Are funds buying GH calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own GH
No. of Funds

Unveiling Guardant Health Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
9.18%
11,130,601
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 09, 2024
capital international investors
3.4%
4,013,661
SC 13G/A
Jan 29, 2024
baillie gifford & co
5.24%
6,178,812
SC 13G
Jan 25, 2024
blackrock inc.
8.9%
10,831,716
SC 13G/A
Mar 10, 2023
fmr llc
-
0
SC 13G/A
Feb 14, 2023
viking global investors lp
4.0%
4,107,644
SC 13G/A
Feb 13, 2023
capital international investors
7.7%
7,879,355
SC 13G
Feb 13, 2023
capital research global investors
2.0%
2,001,782
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A

Recent SEC filings of Guardant Health Inc

View All Filings
Date Filed Form Type Document
Apr 12, 2024
SC 13G
Major Ownership Report
Apr 05, 2024
4
Insider Trading
Apr 02, 2024
4
Insider Trading
Apr 02, 2024
4
Insider Trading
Apr 02, 2024
4
Insider Trading
Apr 02, 2024
4
Insider Trading
Apr 02, 2024
4
Insider Trading
Apr 01, 2024
4
Insider Trading
Apr 01, 2024
4
Insider Trading
Apr 01, 2024
4
Insider Trading

Peers (Alternatives to Guardant Health Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
177.5B
23.9B
-6.01% -5.66%
37.43
7.43
-10.33% -33.23%
41.4B
3.7B
-7.85% 3.70%
48.95
11.3
8.72% 24.44%
41.2B
6.7B
-4.79% -0.38%
33.37
6.12
-2.81% -6.58%
14.2B
9.3B
-0.68% -9.91%
16.66
1.54
-6.38% -9.73%
13.0B
2.5B
16.81% 6.46%
-63.45
5.18
19.93% 67.26%
12.4B
4.1B
-7.63% 17.34%
26.1
3
3.86% -2.39%
12.2B
1.9B
-3.01% 103.01%
43.03
6.45
29.17% 15.26%
11.4B
1.1B
6.13% 81.38%
-26.22
10.53
31.99% 20.63%
MID-CAP
2.7B
929.2M
-20.76% -25.66%
1.7K
2.88
28.93% 111.61%
2.2B
563.9M
-3.74% -26.28%
-4.64
3.95
25.45% 26.76%
SMALL-CAP
440.6M
280.3M
-19.18% -10.04%
-2.32
1.57
-12.89% -148.37%
86.5M
31.2M
-2.40% -86.64%
-0.98
2.77
5.03% -1.81%
42.6M
9.2M
-5.99% -38.94%
-2.55
4.65
11.85% 44.12%
6.5M
9.0M
-20.83% -63.11%
-0.89
0.72
-53.31% 2.21%
183.8K
25.9M
-50.00% -94.83%
-0.01
0.01
-57.78% -93.11%

Guardant Health Inc News

Latest updates
Defense World3 hours ago
Seeking Alpha23 Feb 202408:00 am
Nasdaq23 Feb 202408:00 am

Guardant Health Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue8.4%155,054,000143,030,000137,150,000128,714,000126,891,000117,404,000109,144,00096,099,000108,108,00094,779,00092,101,00078,665,00078,316,00074,569,00066,335,00067,510,00062,897,00060,848,00053,975,00036,655,00032,873,000
Costs and Expenses37.4%352,565,000256,573,000256,766,000262,769,000273,010,000262,004,000239,465,000219,437,000206,316,000202,067,000189,743,000186,528,000169,482,000148,821,000120,955,000102,422,00088,859,00078,325,00069,243,00060,319,00060,260,000
  S&GA Expenses14.8%79,127,00068,934,00071,043,00076,123,00081,423,00080,370,00073,603,00064,432,00059,599,00050,228,00047,716,00034,338,00031,288,00025,095,00025,015,00025,115,00022,287,00018,802,00019,439,00017,807,00017,114,000
  R&D Expenses-4.3%89,856,00093,851,00090,359,00093,128,000106,578,000100,017,00085,455,00081,757,00073,021,00070,968,00063,724,00055,508,00040,282,00036,245,00036,319,00037,016,00025,875,00024,569,00019,532,00016,316,00016,652,000
EBITDA Margin-6.7%-0.77-0.72-0.91-1.29-1.37-1.28-1.23-0.95-0.96-1.10-1.06-1.00---------
Interest Expenses0.2%645,000644,000645,000644,000644,000644,000645,000644,000643,000644,000644,000646,0004,736,0008,00010,00012,000321,000280,000287,000293,000299,000
Income Taxes-210.4%-541,000490,000496,000240,000602,000115,000446,000-24,00011,00096,00083,000110,000263,00068,00034,00014,000-489,000-202,000-1,207,00026,00035,000
Earnings Before Taxes-119.1%-187,584,000-85,612,000-72,275,000-133,293,000-139,332,000-161,879,000-228,986,000-123,252,000-72,300,000-107,430,000-97,492,000-107,248,000-92,782,000-71,602,000-49,705,000-31,815,000-22,599,000-13,292,000-12,507,000-21,325,000-25,237,000
EBT Margin-5.7%-0.85-0.80-0.99-1.38-1.45-1.36-1.30-1.02-1.03-1.18-1.14-1.08---------
Net Income-117.2%-187,043,000-86,102,000-72,771,000-133,533,000-139,934,000-161,994,000-229,432,000-123,228,000-72,311,000-107,526,000-97,575,000-107,358,000-93,045,000-71,670,000-49,739,000-31,829,000-22,110,000-13,090,000-11,300,000-21,351,000-25,272,000
Net Income Margin-5.4%-0.85-0.81-1.00-1.38-1.46-1.36-1.30-1.02-1.03-1.18-1.14-1.08---------
Free Cashflow-3.3%-82,805,000-80,163,000-100,528,000-81,965,000-100,750,000-99,886,000-134,969,000-51,319,000-101,613,000-75,294,000-81,268,000-25,877,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-0.6%1,7861,7971,8401,5121,6101,7021,8542,1302,2042,2262,2922,3472,2721,2621,278948963948940579587
  Current Assets0.0%1,3471,3471,3981,1041,1921,1311,0371,1131,1141,5931,8912,0331,8881,0871,010607597583604512469
    Cash Equivalents147.9%1,134457271224142158215574492832939869833143165152143147175154141
  Inventory-19.6%62.0077.0061.0046.0052.0063.0060.0037.0031.0025.0026.0029.0023.0028.0020.0025.0015.0015.0014.0010.009.00
  Net PPE-1.7%14514815616316816816315112410690.0072.0063.0062.0057.0047.0044.0041.0035.0031.0031.00
  Goodwill0%3.003.003.003.003.003.003.003.003.003.003.003.003.003.003.003.003.003.00---
Liabilities3.7%1,6281,5691,5471,5561,5501,5351,5351,5971,5591,4571,4441,44091611411311811586.0078.0065.0062.00
  Current Liabilities-9.2%20622720120419317516822919510297.0096.0067.0072.0070.0082.0073.0068.0057.0048.0047.00
  Long Term Debt0.1%1,1401,1391,1391,1381,1371,1371,1361,1351,1351,1341,1341,133806--------
    LT Debt, Non Current0.1%1,1401,1391,1391,1381,1371,1371,1361,1351,1351,1341,1341,133806--------
Shareholder's Equity-30.5%159228293-60.001673195336457097888471,2981,0921,115785798815815468483
  Retained Earnings-9.6%-2,141-1,954-1,868-1,795-1,662-1,522-1,360-1,131-1,007-916-809-711-606-512-435-380-352-327-314-303-280
  Additional Paid-In Capital5.3%2,3042,1892,1701,7641,7421,7161,7041,6821,6581,6271,5971,5581,9021,6011,5441,1581,1501,1421,129771764
Shares Outstanding3.2%122118118103103102102102101101101101---------
Float---4,100---4,000---12,100---7,600---3,400--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-1.2%-78,728-77,791-94,015-74,441-90,749-78,160-111,935-28,619-76,988-53,145-62,593-16,291-59,223-8,057-23,365-13,282-30,3421,347-13,836-4,303-26,538
  Share Based Compensation11.5%24,32021,81922,35422,26623,70320,63925,54424,79926,85735,01634,50755,06956,76255,19825,8156,3385,0725,4843,2163,1822,563
Cashflow From Investing154.5%663,454260,699-241,127157,22470,62741,274-72,893110,808-266,697-47,394127,066123,870-297,685-14,656-325,54920,80423,358-35,730-320,52715,329-197,688
Cashflow From Financing2279.0%90,5683,807383,854-8542,318-19,312-172,087-12.003,780-5,5604,909-69,9531,046,724797361,3201,4663,0776,871355,0682,288250,364
  Buy Backs----------------------

GH Income Statement

2023-12-31
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenue:   
Precision oncology testing$ 514,249$ 392,049$ 304,312
Development services and other49,69957,48969,341
Total revenue563,948449,538373,653
Costs and operating expenses:   
Cost of precision oncology testing205,528148,199110,396
Cost of development services and other21,5248,12612,516
Research and development expense367,194373,807263,221
Sales and marketing expense295,227299,828191,881
General and administrative expense155,800163,956206,640
Other operating expense83,40000
Total costs and operating expenses1,128,673993,916784,654
Loss from operations(564,725)(544,378)(411,001)
Interest income35,3656,0693,930
Interest expense(2,578)(2,577)(2,577)
Other income (expense), net53,174(12,778)25,178
Fair value adjustments of noncontrolling interest liability0(99,785)0
Loss before provision for income taxes(478,764)(653,449)(384,470)
Provision for income taxes6851,139300
Net loss(479,449)(654,588)(384,770)
Adjustment of redeemable noncontrolling interest00(20,900)
Net loss attributable to Guardant Health, Inc. common stockholders - basic(479,449)(654,588)(405,670)
Net loss attributable to Guardant Health, Inc. common stockholders - diluted$ (479,449)$ (654,588)$ (405,670)
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in usd per share)$ (4.28)$ (6.41)$ (4.00)
Net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in usd per share)$ (4.28)$ (6.41)$ (4.00)
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic (in shares)111,988102,178101,314
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, diluted (in shares)111,988102,178101,314

GH Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 1,133,537$ 141,647
Short-term marketable debt securities35,097869,584
Accounts receivable, net88,78397,256
Inventory, net61,94851,598
Prepaid expenses and other current assets, net27,74131,509
Total current assets1,347,1061,191,594
Property and equipment, net145,096167,920
Right-of-use assets, net157,616174,001
Intangible assets, net8,97911,727
Goodwill3,2903,290
Other assets, net124,33461,453
Total Assets1,786,4211,609,985
Current liabilities:  
Accounts payable and accrued liabilities187,952175,817
Deferred revenue17,96517,403
Total current liabilities205,917193,220
Convertible senior notes, net1,139,9661,137,391
Long-term operating lease liabilities185,848210,015
Other long-term liabilities96,0069,179
Total Liabilities1,627,7371,549,805
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized, no shares issued and outstanding as of December 31, 2023 and 202200
Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of December 31, 2023 and 2022; 121,629,861 and 102,619,383 shares issued and outstanding as of December 31, 2023 and 2022, respectively11
Additional paid-in capital2,304,2201,742,114
Accumulated other comprehensive loss(3,675)(19,522)
Accumulated deficit(2,141,862)(1,662,413)
Total Stockholders’ Equity158,68460,180
Total Liabilities and Stockholders’ Equity$ 1,786,421$ 1,609,985
GH
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360; Guardant360 LDT; Guardant360 CDx; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It also offers Shield Test; Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, a suite of advanced analytical technologies to enhance the performance and clinical utility of cancer tests. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. Guardant Health, Inc. has a research collaboration agreement with the Parker Institute for Cancer Immunotherapy to study the correlation between molecular cancer biomarkers and patient response to immunotherapy treatment across various types of cancer. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
 CEO
 WEBSITEhttps://guardanthealth.com
 INDUSTRYDiagnostics & Research
 EMPLOYEES1793

Guardant Health Inc Frequently Asked Questions


What is the ticker symbol for Guardant Health Inc? What does GH stand for in stocks?

GH is the stock ticker symbol of Guardant Health Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Guardant Health Inc (GH)?

As of Fri Apr 12 2024, market cap of Guardant Health Inc is 2.23 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GH stock?

You can check GH's fair value in chart for subscribers.

What is the fair value of GH stock?

You can check GH's fair value in chart for subscribers. The fair value of Guardant Health Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Guardant Health Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Guardant Health Inc a good stock to buy?

The fair value guage provides a quick view whether GH is over valued or under valued. Whether Guardant Health Inc is cheap or expensive depends on the assumptions which impact Guardant Health Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GH.

What is Guardant Health Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 12 2024, GH's PE ratio (Price to Earnings) is -4.64 and Price to Sales (PS) ratio is 3.95. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GH PE ratio will change depending on the future growth rate expectations of investors.